{"id":"NCT00397189","sponsor":"Neurim Pharmaceuticals Ltd.","briefTitle":"Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients","officialTitle":"A Double-blind, Parallel Group, Randomised, Placebo Controlled Study of Efficacy and Safety of Circadin® 2 mg in the Treatment of Insomnia Patients With Low Endogenous Melatonin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-10","primaryCompletion":"2008-12","completion":"2009-04","firstPosted":"2006-11-08","resultsPosted":"2011-03-28","lastUpdate":"2018-05-01"},"enrollment":930,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Insomnia"],"interventions":[{"type":"DRUG","name":"Circadin","otherNames":["ATC code: N05CH01"]},{"type":"DRUG","name":"placebo circadin","otherNames":[]}],"arms":[{"label":"Circadin","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomised, placebo controlled study to evaluate the efficacy of a 3 week treatment period with Circadin® 2 mg in shortening sleep latency in patients with primary insomnia aged 18-80 with melatonin deficiency.","primaryOutcome":{"measure":"The Change From Baseline in Subjective Sleep Latency.","timeFrame":"Baseline and 3 weeks","effectByArm":[{"arm":"Circadin","deltaMin":-19.1,"sd":47.3},{"arm":"Placebo","deltaMin":-1.7,"sd":47.8}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.05"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":8},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":["21091391","20712869"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":394},"commonTop":["nasopharyngitis","headache","upper respiratory tract infection"]}}